(.venv_embed) hilarious_marcupial@DESKTOP-KOMPK5V:/mnt/c/Users/dylan/2ndOpinionMD-MVP$ bash scripts/portalnode
4090_source_router_harness.sh   --questions-file server/scripts/eoh_source_router_questions_10.txt   --max-sou
rces 8   --max-modules 6   --out receipts/EOH_LLAMA_3.2_FORWARD_ROUTING_BATCH10_20260425.json
🚀 Starting EoH source-router harness
📚 Reading questions file: server/scripts/eoh_source_router_questions_10.txt
❓ Loaded 10 question(s)
📚 Loaded source candidates: 38
🧩 Loaded module candidates: 41
📚 Batch mode enabled
➡️ Batch question 1/10: First-line therapy for T2DM with CKD considerations
🤖 Ollama call model=eoh-llama3.2-source-router num_ctx=8192 timeout=120s
✅ Router model completed in 4.994s
➡️ Batch question 2/10: How should we route sources for anemia management in CKD with diabetes?
🤖 Ollama call model=eoh-llama3.2-source-router num_ctx=8192 timeout=120s
✅ Router model completed in 1.387s
➡️ Batch question 3/10: What sources and modules should guide steroid-sparing plan for lupus nephritis?
🤖 Ollama call model=eoh-llama3.2-source-router num_ctx=8192 timeout=120s
✅ Router model completed in 1.813s
➡️ Batch question 4/10: Route this question: worsening dyspnea in COPD with possible guideline escalation
🤖 Ollama call model=eoh-llama3.2-source-router num_ctx=8192 timeout=120s
✅ Router model completed in 1.537s
➡️ Batch question 5/10: Which sources should we search for asthma step-up and adherence barriers?
🤖 Ollama call model=eoh-llama3.2-source-router num_ctx=8192 timeout=120s
✅ Router model completed in 1.227s
➡️ Batch question 6/10: Query planning for opioid prescribing risk mitigation in chronic pain patient
🤖 Ollama call model=eoh-llama3.2-source-router num_ctx=8192 timeout=120s
✅ Router model completed in 1.624s
➡️ Batch question 7/10: How to route evidence for rheumatoid arthritis flare vs infection overlap
🤖 Ollama call model=eoh-llama3.2-source-router num_ctx=8192 timeout=120s
✅ Router model completed in 1.092s
➡️ Batch question 8/10: Source routing for ANCA-associated vasculitis with renal decline
🤖 Ollama call model=eoh-llama3.2-source-router num_ctx=8192 timeout=120s
✅ Router model completed in 1.943s
➡️ Batch question 9/10: Route retrieval for psoriatic arthritis treatment options with CKD comorbidity
🤖 Ollama call model=eoh-llama3.2-source-router num_ctx=8192 timeout=120s
✅ Router model completed in 1.680s
➡️ Batch question 10/10: What modules and sources should be prioritized for unexplained inflammatory markers t
rend
🤖 Ollama call model=eoh-llama3.2-source-router num_ctx=8192 timeout=120s
✅ Router model completed in 1.988s
{
  "batch": {
    "n_questions": 10,
    "elapsed_sec": 19.287,
    "model": "eoh-llama3.2-source-router",
    "max_sources": 8,
    "max_modules": 6
  },
  "runs": [
    {
      "query": "First-line therapy for T2DM with CKD considerations",
      "model": "eoh-llama3.2-source-router",
      "max_sources": 8,
      "max_modules": 6,
      "source_candidates_count": 38,
      "module_candidates_count": 41,
      "route_plan": {
        "question_type": "E",
        "semantic_query": "First-line therapy for T2DM with CKD considerations",
        "ts_query": "(T2DM OR \"diabetes mellitus\") AND (CKD OR \"chronic kidney disease\")",
        "ts_terms": [
          "T2DM",
          "CKD"
        ],
        "selected_sources": [
          {
            "source": "kdigo_ckd_2021",
            "priority": 1,
            "why": "KDIGO 2021 CKD evaluation and management guideline excerpts"
          },
          {
            "source": "ada_dm_2024",
            "priority": 2,
            "why": "American Diabetes Association Standards of Care (diabetes mellitus, 2024 vintage)"
          },
          {
            "source": "rxnorm",
            "priority": 3,
            "why": "NLM RxNorm drug and ingredient concepts (RxCUI, names, TTYs)"
          },
          {
            "source": "loinc",
            "priority": 4,
            "why": "LOINC laboratory and clinical observation codes with long names."
          },
          {
            "source": "hpo",
            "priority": 5,
            "why": "Human Phenotype Ontology terms (phenotypes, disease manifestations)"
          },
          {
            "source": "snomed",
            "priority": 6,
            "why": "SNOMED CT clinical concepts (disorders, findings, procedures)"
          },
          {
            "source": "icd10cm",
            "priority": 7,
            "why": "ICD-10-CM diagnosis codes and official long titles (US clinical modification)"
          },
          {
            "source": "orphanet",
            "priority": 8,
            "why": "Orphanet rare disease names, synonyms, and classification text"
          }
        ],
        "selected_modules": [
          {
            "module_id": "M13",
            "priority": 1,
            "why": "Trend & Prognostic Engine"
          },
          {
            "module_id": "M6",
            "priority": 2,
            "why": "Escalation Router / Central Switchboard"
          },
          {
            "module_id": "M12",
            "priority": 3,
            "why": "Symptom Narrative Engine"
          },
          {
            "module_id": "M7A",
            "priority": 4,
            "why": "Data Quality & Sanity Checks"
          },
          {
            "module_id": "M9",
            "priority": 5,
            "why": "Suppression Core (Policy)"
          },
          {
            "module_id": "M10",
            "priority": 6,
            "why": "Crisis Engine / Critical Escalation"
          }
        ],
        "notes": "Use KDIGO CKD guidelines for T2DM with CKD considerations"
      },
      "batch_index": 1
    },
    {
      "query": "How should we route sources for anemia management in CKD with diabetes?",
      "model": "eoh-llama3.2-source-router",
      "max_sources": 8,
      "max_modules": 6,
      "source_candidates_count": 38,
      "module_candidates_count": 41,
      "route_plan": {
        "question_type": "E",
        "semantic_query": "How should we route sources for anemia management in CKD with diabetes?",
        "ts_query": "anemia AND (CKD OR diabetes)",
        "ts_terms": [
          "anemia",
          "CKD",
          "diabetes"
        ],
        "selected_sources": [
          {
            "source": "rxnorm",
            "priority": 1,
            "why": "RxNorm provides comprehensive drug and ingredient information"
          },
          {
            "source": "loinc",
            "priority": 2,
            "why": "LOINC offers a wide range of laboratory and clinical observation codes"
          }
        ],
        "selected_modules": [
          {
            "module_id": "M13",
            "priority": 1,
            "why": "Trend & Prognostic Engine provides flare risk over next X days/months"
          },
          {
            "module_id": "M6",
            "priority": 2,
            "why": "Escalation Router / Central Switchboard chooses severity tier and who should be notified"
          }
        ],
        "notes": "Route sources for anemia management in CKD with diabetes using RxNorm and LOINC, and use Tre
nd & Prognostic Engine and Escalation Router / Central Switchboard"
      },
      "batch_index": 2
    },
    {
      "query": "What sources and modules should guide steroid-sparing plan for lupus nephritis?",
      "model": "eoh-llama3.2-source-router",
      "max_sources": 8,
      "max_modules": 6,
      "source_candidates_count": 38,
      "module_candidates_count": 41,
      "route_plan": {
        "question_type": "E",
        "semantic_query": "steroid-sparing plan for lupus nephritis",
        "ts_query": "lupus AND nephritis AND steroid-sparing",
        "ts_terms": [
          "lupus",
          "nephritis",
          "steroid-sparing"
        ],
        "selected_sources": [
          {
            "source": "kdigo_ckd_2024",
            "priority": 1,
            "why": "specific guideline on lupus nephritis"
          },
          {
            "source": "eular_sle_nephritis_2025",
            "priority": 2,
            "why": "EULAR recommendations on management of lupus nephritis"
          },
          {
            "source": "kdigo_gn_ln_2021",
            "priority": 3,
            "why": "KDIGO guideline for glomerular diseases including lupus nephritis"
          }
        ],
        "selected_modules": [
          {
            "module_id": "M13",
            "priority": 1,
            "why": "Trend & Prognostic Engine can reason about flare risk and trajectory"
          },
          {
            "module_id": "M6",
            "priority": 2,
            "why": "Escalation Router / Central Switchboard can choose severity tier and notify relevant parti
es"
          },
          {
            "module_id": "M12",
            "priority": 3,
            "why": "Symptom Narrative Engine can summarize free text into digest + structured findings"
          }
        ],
        "notes": "Use a combination of sources to guide steroid-sparing plan for lupus nephritis. Consider fla
re risk and trajectory with Trend & Prognostic Engine, escalate severity tier with Escalation Router / Central
 Switchboard, and summarize symptoms with Symptom Narrative Engine."
      },
      "batch_index": 3
    },
    {
      "query": "Route this question: worsening dyspnea in COPD with possible guideline escalation",
      "model": "eoh-llama3.2-source-router",
      "max_sources": 8,
      "max_modules": 6,
      "source_candidates_count": 38,
      "module_candidates_count": 41,
      "route_plan": {
        "question_type": "E",
        "semantic_query": "worsening dyspnea in COPD with possible guideline escalation",
        "ts_query": "(dyspnea OR shortness of breath) AND (COPD OR chronic obstructive pulmonary disease)",
        "ts_terms": [
          "dyspnea",
          "shortness of breath",
          "COPD"
        ],
        "selected_sources": [
          {
            "source": "gold_copd_2023",
            "priority": 1,
            "why": "relevant COPD guideline"
          },
          {
            "source": "rxnorm",
            "priority": 2,
            "why": "comprehensive drug and ingredient concepts"
          },
          {
            "source": "loinc",
            "priority": 3,
            "why": "useful laboratory and clinical observation codes"
          }
        ],
        "selected_modules": [
          {
            "module_id": "M13",
            "priority": 1,
            "why": "Trend & Prognostic Engine for flare risk"
          },
          {
            "module_id": "M6",
            "priority": 2,
            "why": "Escalation Router / Central Switchboard for severity tier selection"
          },
          {
            "module_id": "M12",
            "priority": 3,
            "why": "Symptom Narrative Engine for compressed narrative"
          }
        ],
        "notes": "Use a combination of COPD guidelines and comprehensive drug concepts to inform flare risk as
sessment"
      },
      "batch_index": 4
    },
    {
      "query": "Which sources should we search for asthma step-up and adherence barriers?",
      "model": "eoh-llama3.2-source-router",
      "max_sources": 8,
      "max_modules": 6,
      "source_candidates_count": 38,
      "module_candidates_count": 41,
      "route_plan": {
        "question_type": "E",
        "semantic_query": "asthma step-up and adherence barriers",
        "ts_query": "asthma AND (step-up OR adherence)",
        "ts_terms": [
          "asthma",
          "step-up",
          "adherence"
        ],
        "selected_sources": [
          {
            "source": "rxnorm",
            "priority": 1,
            "why": "RxNorm provides a comprehensive list of drug and ingredient concepts that can be used to s
earch for asthma-related terms."
          }
        ],
        "selected_modules": [
          {
            "module_id": "M13",
            "priority": 1,
            "why": "The Trend & Prognostic Engine (M13) is well-suited for identifying flare risk over time an
d can provide insights into asthma trajectory improvement or worsening."
          }
        ],
        "notes": "For this query, we selected RxNorm as the source due to its comprehensive coverage of drug a
nd ingredient concepts. We chose M13 as the module because it provides prognostic capabilities that are releva
nt to assessing asthma flare risk."
      },
      "batch_index": 5
    },
    {
      "query": "Query planning for opioid prescribing risk mitigation in chronic pain patient",
      "model": "eoh-llama3.2-source-router",
      "max_sources": 8,
      "max_modules": 6,
      "source_candidates_count": 38,
      "module_candidates_count": 41,
      "route_plan": {
        "question_type": "E",
        "semantic_query": "oxygen therapy for chronic pain patient with opioid use disorder",
        "ts_query": "(oxygen OR oxygen therapy) AND (chronic pain OR chronic pain management) AND (opioid OR o
pioid use disorder)",
        "ts_terms": [
          "oxygen",
          "pain",
          "opioid"
        ],
        "selected_sources": [
          {
            "source": "rxnorm",
            "priority": 1,
            "why": "RxNorm provides comprehensive information on medications and their uses"
          },
          {
            "source": "loinc",
            "priority": 2,
            "why": "LOINC codes provide standardized laboratory and clinical observation terms"
          },
          {
            "source": "hpo",
            "priority": 3,
            "why": "Human Phenotype Ontology terms offer a rich resource for phenotypic descriptions"
          }
        ],
        "selected_modules": [
          {
            "module_id": "M13",
            "priority": 1,
            "why": "Trend & Prognostic Engine can analyze flare risk over time"
          },
          {
            "module_id": "M6",
            "priority": 2,
            "why": "Escalation Router / Central Switchboard can choose severity tier and notify relevant parti
es"
          },
          {
            "module_id": "M12",
            "priority": 3,
            "why": "Symptom Narrative Engine can summarize free text into digest + structured findings"
          }
        ],
        "notes": "Use oxygen therapy as an adjunct to chronic pain management in patients with opioid use diso
rder"
      },
      "batch_index": 6
    },
    {
      "query": "How to route evidence for rheumatoid arthritis flare vs infection overlap",
      "model": "eoh-llama3.2-source-router",
      "max_sources": 8,
      "max_modules": 6,
      "source_candidates_count": 38,
      "module_candidates_count": 41,
      "route_plan": {
        "question_type": "E",
        "semantic_query": "How to route evidence for rheumatoid arthritis flare vs infection overlap",
        "ts_query": "IN ('rheumatoid arthritis', 'infection')",
        "ts_terms": [
          "rheumatoid arthritis",
          "infection"
        ],
        "selected_sources": [
          {
            "source": "rxnorm",
            "priority": 1,
            "why": "short reason"
          },
          {
            "source": "loinc",
            "priority": 2,
            "why": "medium reason"
          }
        ],
        "selected_modules": [
          {
            "module_id": "M13",
            "priority": 1,
            "why": "high priority"
          },
          {
            "module_id": "M7A",
            "priority": 2,
            "why": "medium priority"
          }
        ],
        "notes": "Use a combination of flare and infection detection to route evidence"
      },
      "batch_index": 7
    },
    {
      "query": "Source routing for ANCA-associated vasculitis with renal decline",
      "model": "eoh-llama3.2-source-router",
      "max_sources": 8,
      "max_modules": 6,
      "source_candidates_count": 38,
      "module_candidates_count": 41,
      "route_plan": {
        "question_type": "E",
        "semantic_query": "Source routing for ANCA-associated vasculitis with renal decline",
        "ts_query": "IN ('renal decline', 'ANCA-associated vasculitis')",
        "ts_terms": [
          "renal decline",
          "ANCA-associated vasculitis"
        ],
        "selected_sources": [
          {
            "source": "rxnorm",
            "priority": 1,
            "why": "RxNorm provides a comprehensive list of drug and ingredient concepts that may be relevant
to ANCA-associated vasculitis"
          },
          {
            "source": "loinc",
            "priority": 2,
            "why": "LOINC laboratory and clinical observation codes provide detailed information on renal func
tion and other relevant health indicators"
          },
          {
            "source": "hpo",
            "priority": 3,
            "why": "Human Phenotype Ontology terms offer a standardized way to describe the phenotypes associa
ted with ANCA-associated vasculitis"
          }
        ],
        "selected_modules": [
          {
            "module_id": "M13",
            "priority": 1,
            "why": "Trend & Prognostic Engine is well-suited for analyzing flare risk and trajectory over time
"
          },
          {
            "module_id": "M6",
            "priority": 2,
            "why": "Escalation Router / Central Switchboard can help determine the severity tier and who shoul
d be notified based on state transitions"
          },
          {
            "module_id": "M12",
            "priority": 3,
            "why": "Symptom Narrative Engine can provide a compressed but faithful view of what's been happeni
ng over days/weeks"
          }
        ],
        "notes": "This routing plan leverages RxNorm, LOINC, and HPO to identify relevant health concepts, and
 Trend & Prognostic Engine, Escalation Router / Central Switchboard, and Symptom Narrative Engine to analyze f
lare risk and trajectory"
      },
      "batch_index": 8
    },
    {
      "query": "Route retrieval for psoriatic arthritis treatment options with CKD comorbidity",
      "model": "eoh-llama3.2-source-router",
      "max_sources": 8,
      "max_modules": 6,
      "source_candidates_count": 38,
      "module_candidates_count": 41,
      "route_plan": {
        "question_type": "E",
        "semantic_query": "Route retrieval for psoriatic arthritis treatment options with CKD comorbidity",
        "ts_query": "psoriatic arthritis AND chronic kidney disease",
        "ts_terms": [
          "psoriatic arthritis",
          "chronic kidney disease"
        ],
        "selected_sources": [
          {
            "source": "kdigo_ckd_2021",
            "priority": 1,
            "why": "CKD guideline"
          },
          {
            "source": "loinc",
            "priority": 3,
            "why": "Lab and clinical observation codes"
          },
          {
            "source": "hpo",
            "priority": 4,
            "why": "Human Phenotype Ontology terms"
          }
        ],
        "selected_modules": [
          {
            "module_id": "M13",
            "priority": 1,
            "why": "Flare risk over next X days/months"
          },
          {
            "module_id": "M6",
            "priority": 2,
            "why": "Escalation Router / Central Switchboard"
          },
          {
            "module_id": "M4",
            "priority": 3,
            "why": "Reflex Suppression Audit Trail"
          },
          {
            "module_id": "M12",
            "priority": 4,
            "why": "Symptom Narrative Engine"
          }
        ],
        "notes": "Use EoH to route retrieval for psoriatic arthritis treatment options with CKD comorbidity"
      },
      "batch_index": 9
    },
    {
      "query": "What modules and sources should be prioritized for unexplained inflammatory markers trend",
      "model": "eoh-llama3.2-source-router",
      "max_sources": 8,
      "max_modules": 6,
      "source_candidates_count": 38,
      "module_candidates_count": 41,
      "route_plan": {
        "question_type": "E",
        "semantic_query": "What modules and sources should be prioritized for unexplained inflammatory markers
 trend? (e.g., patient terrain, CBM & Baseline Drift Engine, Stability Score to Band Engine)",
        "ts_query": "inflamed OR inflammation",
        "ts_terms": [
          "inflammation",
          "flare risk",
          "flare probability"
        ],
        "selected_sources": [
          {
            "source": "rxnorm",
            "priority": 1,
            "why": "RxNorm provides a comprehensive list of drug and ingredient concepts that can be related t
o inflammatory markers"
          },
          {
            "source": "loinc",
            "priority": 2,
            "why": "LOINC laboratory and clinical observation codes provide a standardized vocabulary for labo
ratory results that may indicate inflammation"
          },
          {
            "source": "hpo",
            "priority": 3,
            "why": "Human Phenotype Ontology terms offer a rich resource for understanding the phenotypic mani
festations of inflammatory conditions"
          }
        ],
        "selected_modules": [
          {
            "module_id": "M13",
            "priority": 1,
            "why": "Trend & Prognostic Engine is well-suited to analyze flare risk and probability over time"
          },
          {
            "module_id": "M4",
            "priority": 2,
            "why": "Reflex Suppression Audit Trail can help identify patterns of suppression that may indicate
 underlying inflammatory conditions"
          },
          {
            "module_id": "M12",
            "priority": 3,
            "why": "Symptom Narrative Engine can provide a compressed view of patient symptoms and flare histo
ry"
          }
        ],
        "notes": "Prioritizing sources from RxNorm, LOINC, and HPO can help identify potential causes of unexp
lained inflammatory markers. Modules M13, M4, and M12 are selected for their ability to analyze flare risk, id
entify patterns of suppression, and provide a narrative view of patient symptoms"
      },
      "batch_index": 10
    }
  ]
}
💾 Wrote output file: receipts/EOH_LLAMA_3.2_FORWARD_ROUTING_BATCH10_20260425.json
🏁 Source-router harness complete

---

## Meta-commentary (assistant)

- The 10-query batch completed successfully and emitted valid JSON route plans through `batch_index=10`, indicating harness stability in batch mode.
- The final run’s rationale is coherent: selected sources (`rxnorm`, `loinc`, `hpo`) and modules (`M13`, `M4`, `M12`) align with the prompt intent around unexplained inflammatory marker patterns and symptom-context interpretation.
- Planning quality appears stronger than the first nascent single-query run (which was under-selective), suggesting the 3.2 router benefits from repeated prompt exposure and explicit candidate constraints.
- Remaining risk: route plans can still be semantically plausible but operationally under-broad for complex queries; enforce a minimum source/module count by question type (e.g., C/D/E) to improve recall.
- Recommended next eval: compute batch-level metrics (question_type distribution, mean selected source count, mean selected module count, lexical expansion length) and compare against retrieval overlap/answer quality from the MKG batch harness.